ALEC Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -1063.41% compared to Alector, Inc.'s net margin of 16.99%. Alector, Inc.'s return on equity of -114.8% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Alector, Inc. has a consensus price target of $2.10, signalling upside risk potential of 12.3%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $467.62 which suggests that it could grow by 48.74%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Alector, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Alector, Inc..

Alector, Inc. has a beta of 0.643, which suggesting that the stock is 35.655% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Alector, Inc.'s net income of -$34.7M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Alector, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 2.71x versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -1063.41% compared to Alector, Inc.'s net margin of -3.91%. Alector, Inc.'s return on equity of -114.8% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.

Alector, Inc. has a consensus price target of $2.10, signalling upside risk potential of 12.3%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.65 which suggests that it could grow by 48.07%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Alector, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Alector, Inc..

Alector, Inc. has a beta of 0.643, which suggesting that the stock is 35.655% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Alector, Inc.'s net income of -$34.7M is lower than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Alector, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 2.71x versus 3.79x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -1063.41% compared to Alector, Inc.'s net margin of --. Alector, Inc.'s return on equity of -114.8% beat Savara, Inc.'s return on equity of -78.83%.

Alector, Inc. has a consensus price target of $2.10, signalling upside risk potential of 12.3%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.08%. Given that Savara, Inc. has higher upside potential than Alector, Inc., analysts believe Savara, Inc. is more attractive than Alector, Inc..

Alector, Inc. has a beta of 0.643, which suggesting that the stock is 35.655% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are larger than Savara, Inc. quarterly revenues of --. Alector, Inc.'s net income of -$34.7M is lower than Savara, Inc.'s net income of -$29.6M. Notably, Alector, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 2.71x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of -1063.41% compared to Alector, Inc.'s net margin of -6237.29%. Alector, Inc.'s return on equity of -114.8% beat Vistagen Therapeutics, Inc.'s return on equity of -96.95%.

Alector, Inc. has a consensus price target of $2.10, signalling upside risk potential of 12.3%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 91.19%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Alector, Inc., analysts believe Vistagen Therapeutics, Inc. is more attractive than Alector, Inc..

Alector, Inc. has a beta of 0.643, which suggesting that the stock is 35.655% less volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.324, suggesting its less volatile than the S&P 500 by 67.572%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $303K. Alector, Inc.'s net income of -$34.7M is lower than Vistagen Therapeutics, Inc.'s net income of -$18.9M. Notably, Alector, Inc.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 2.71x versus 17.11x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.